newsfilter
← Latest News
Business Wire·

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, "PMV Pharma")) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling test,